November 14th 2024
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
The Significance of Brain Metastases in Non-Small Cell Lung Cancer
March 21st 2018Robert C. Doebele, MD, PhD, associate professor in the Division of Medical Oncology at the University of Colorado, discusses the significance of brain metastases in patients with non–small cell lung cancer.
Watch
PFS Improved in Frontline Squamous NSCLC with Atezolizumab Plus Chemo
March 20th 2018According to topline findings from the phase III IMpower131 trial, the addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel delayed progression or death compared with chemotherapy alone for patients with advanced squamous non–small cell lung cancer. These results were released by Genentech, the manufacturer of the anti–PD-L1 agent.
Read More
ASCO/CAP Panel Says Evidence Does Not Yet Support ctDNA Testing Outside of Clinical Trials
March 10th 2018After reviewing data from a decade of clinical research, a joint panel from ASCO and the College of American Pathologists concluded that circulating tumor DNA testing should be used only to screen for participation in, or during, a clinical trial.
Read More
Expert Discusses Sequencing With Osimertinib in NSCLC Ahead of FDA's Frontline Decision
March 8th 2018In an interview with<em> Targeted Oncology</em> ahead of the 5th Annual Miami Lung Cancer Conference, Sarah B. Goldberg, MD, discusses the key points of her lecture on testing for and treating resistance to EGFR TKI therapy in NSCLC.
Read More